Sponsor	Phase
Tongji Hospital	NA
Beijing Tiantan Hospital	NA
Jiujiang University Affiliated Hospital	NA

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Osmotica Pharm Corp	KHEDEZLA	desvenlafaxine	TABLET, EXTENDED RELEASE;ORAL	204683-001	Jul 10, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl	DESVENLAFAXINE SUCCINATE	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	204065-003	Jul 29, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Yichang Humanwell	DESVENLAFAXINE SUCCINATE	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	210014-003	Oct 13, 2020	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva Pharms Usa	DESVENLAFAXINE	desvenlafaxine fumarate	TABLET, EXTENDED RELEASE;ORAL	205208-001	Oct 11, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	DESVENLAFAXINE SUCCINATE	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	204083-001	Feb 16, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: January 6, 2026

Summary

Desvenlafaxine (brand name: Pristiq) is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for treating major depressive disorder (MDD). As the first generic equivalent emerged, the drug’s market landscape experienced notable shifts. This analysis explores deasprivenlafaxine's current market dynamics and financial trajectory, encompassing patent status, competitive environment, demand drivers, regulatory influences, pricing strategies, and future outlooks.

What Are the Market Dynamics for Desvenlafaxine?

Patent and Market Exclusivity Status

Aspect	Details	Impact
Patent Expiration	Key patents expired in the US by 2019, opening the space for generic versions.	Led to increased generic entry, reducing branded sales prices and market share.
Data Exclusivity	Data protections expired in most jurisdictions around 2019-2020.	Allowed generics to enter markets more freely.
Regulatory Approvals	First generic approvals granted in the US in 2019, with multiple subsequent approvals.	Increased competitive pressure and price erosion.

Source: U.S. FDA Orange Book, 2022; IQVIA, 2022

Competitive Landscape

Competitors	Market Share (2022, US)	Key Features
Branded Desvenlafaxine (Pristiq)	12%	Original patent-protected drug, premium pricing.
Generic Desvenlafaxine	88%	Multiple suppliers, lower price point, increased access.
Other SNRI drugs (Duloxetine, Venlafaxine)	N/A	Alternative options for depression treatment, affecting market size.

Note: The widespread adoption of generics post-2019 significantly diminished Pristiq's market dominance.

Demand and Prescriber Trends

Trend/Factor	Description	Effect
Rising Depression Prevalence	Global depression rates increased, especially during COVID-19 pandemic.	Elevated demand for effective antidepressants.
Prescriber Preferences	Preference shifted towards cost-effective generics.	Reduced prescribing of branded drugs.
Insurance Coverage	Payers favor generics to reduce costs.	Premium pricing for Branded Pristiq diminished.
Patient Adherence	Once-daily dosing and tolerability maintained, but side effects remain a concern.	Influences overall market volume but less impact on generic uptake.

Source: WHO, 2021; IMS Health, 2022

Pricing Strategies and Revenue Streams

Strategy	Description	Outcome
Patent Conducted Strategies	Branded sales priced at premium levels pre-2019.	High-margin revenue during patent protection phase.
Post-Patent Market Adjustment	Generic competition led to price reductions of approximately 70%.	Revenue decline for branded products; increased volume sales for generics.
Launch of Authorized Generics	Multiple manufacturers launched authorized generics post-expiry.	Further percentage reduction in price; better market penetration for generics.
Direct-to-Consumer Advertising	Limited, primarily in the US.	Slight impact on demand, but overshadowed by price competition.

Source: IQVIA, 2022; FDA, 2021

Regulatory and Reimbursement Policies

Policy Aspect	Impact
US FDA Generic Approval Processes	Streamlined approval pathways increased competition post-2019.
Reimbursement Landscape	Favoring generics in payor formularies, decreasing attractiveness of branded Pristiq.
International Market Regulations	Varying patent laws and approval processes influence global market penetration.

What Is the Financial Trajectory for Desvenlafaxine?

Historical Revenue Performance

Year	Estimated US Sales ($ millions)	Comments
2018	650	Peak branded sales before patent expiry.
2019	150	Sharp decline due to patent expiry and entry of generics.
2020	80	Continued decline, stabilized at low levels.
2021	50	Generic market dominance cemented, market share eroded significantly.
2022	30	Slight further decline, driven primarily by international markets.

Source: IQVIA, 2022

Forecasted Revenue Trends

Projection Period	Expected US Market Revenue ($ millions)	Major Drivers
2023-2025	$20 - $40	Reduced demand, increased generic penetration.
2026-2030	$10 - $20	Market saturation, price erosion, competitive commoditization.

Factors Influencing Future Revenue

Patent and Market Exclusivity: No new patents expected; generics will dominate.
Pricing Pressures: Continued downward price trends for generics.
Market Penetration: International markets show rising adoption but face regulatory hurdles.
Therapeutic Positioning: Competing therapies with improved efficacy or side effect profile could impact demand.

Potential for Value Recovery

Scenario	Description	Impact
Niche Therapeutic Use	Targeting specific patient populations with unmet needs.	Marginally sustains higher prices; limited market size.
Combination Therapies	Incorporation into multi-drug regimens.	May sustain some demand; unlikely to reverse overall decline.
New Formulations or Indications	Development of extended-release versions or new uses.	Could provide revenue uplift but requires R&D investment.

Comparison with Similar SNRI Drugs

Drug Name	Mechanism	Patent Expiry	US Sales (2022)	Primary Market Share	Price per Daily Dose ($)	Remarks
Duloxetine (Cymbalta)	SNRI, broader indication subset	2014 (for some formulations)	$2.1 billion	Dominant in SNRI class	$4.50 - $7.00	Diversified portfolio reduces volatility.
Venlafaxine (Effexor)	SNRI, used for depression & anxiety	Patent expired 2011	$1.0 billion	Moderate	$1.50 - $3.00	Generic availability highly mature.
Desvenlafaxine	SNRI, designed for depression	2019	Declining post-patent	Low/secondary	$3.00 - $4.00	Initially high-priced, now commoditized via generics.

Sources: IQVIA, 2022; FDA Orange Book

Deep Dive: Future Outlook and Strategic Considerations

Parameter	Expected Trends	Strategic Implications
Patent Status	No further patent protections expected.	Focus shifts to generic market share growth and cost leadership.
Market Size	Global depression prevalence increases, but controlled by generics.	Volume-driven growth possible in low-income markets.
Regulatory Environment	Tightening in some regions; expanding in emerging markets.	Navigating local patent and approval processes is essential.
Pricing Strategy	Continued decline in per-unit prices.	Cost efficiency becomes critical for profitability.
Lifecycle Management	Potential new indications or formulations.	Investment in R&D could extend product relevance marginally.

Summary of Market Potential

Region	Estimated Market Size (2022, US$ millions)	Growth Rate (2023-2025)	Key Factors
United States	30	-10% to -20%	Generic dominance, price competition.
Europe	15	-15% to -25%	Similar patent expiry timelines, regulatory hurdles.
Asia-Pacific	10	+5% to +10%	Growing mental health awareness, lower generic penetration.

Key Takeaways

The expiration of patent protections in 2019 significantly altered desvenlafaxine’s market landscape, leading to widespread generic adoption and steep price declines.
Branded desvenlafaxine's revenue has declined sharply since 2019, with projections indicating continued erosion driven by generics and commoditization.
Despite decline, demand persists driven by the global prevalence of depression and the drug's efficacy profile, especially in healthcare systems emphasizing cost-effective treatments.
International markets present growth opportunities, contingent on regulatory approvals, formulary placements, and healthcare infrastructure.
Future revenue growth hinges on strategic differentiation, such as niche indications, new formulations, or combination therapies, though these opportunities remain limited.

FAQs

1. What are the main factors influencing the decline in desvenlafaxine sales post-2019?

The primary drivers are patent expiry, resulting in widespread generic competition, which precipitated drastic price reductions and volume shifts from branded to generic products, diluting revenue streams.

2. How does generic competition impact drug pricing strategies?

Generic competition forces original manufacturers and brand holders to lower prices to remain competitive, often resulting in price erosions upwards of 70%, reducing profit margins but increasing market volume.

3. Are there promising new indications or formulations for desvenlafaxine?

Currently, no significant new indications are approved. Pharmaceutical R&D efforts have focused on alternative SNRIs or combination therapies, with limited pipeline activity specifically for desvenlafaxine.

4. How does desvenlafaxine compare with other SNRI drugs in the market?

Desvenlafaxine's market share and revenue are substantially lower than larger SNRI drugs like duloxetine due to earlier patent expirations and more aggressive generic competition, limiting its market potential compared to peers.

5. What strategic actions can manufacturers pursue to prolong the product's lifecycle?

Strategies include developing novel formulations (e.g., extended-release versions), exploring new therapeutic indications, implementing differentiation in dosing regimens, and focusing on underserved geographic markets.

References

[1] FDA Orange Book, 2022
[2] IQVIA, Market Analysis Reports, 2022
[3] WHO Depression Statistics, 2021
[4] U.S. FDA, Approval Announcements, 2021
[5] International Patent Laws and Market Regulations, 2022

US Patents:	1
Tradenames:	4
Applicants:	15
NDAs:	16
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	75
Patent Applications:	5,181
Drug Prices:	Drug price trends for desvenlafaxine
What excipients (inactive ingredients) are in desvenlafaxine?	desvenlafaxine excipients list
DailyMed Link:	desvenlafaxine at DailyMed

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Desvenlafaxine - Generic Drug Details

What are the generic drug sources for desvenlafaxine and what is the scope of patent protection?

Summary for desvenlafaxine

Recent Clinical Trials for desvenlafaxine

Generic filers with tentative approvals for DESVENLAFAXINE

Pharmacology for desvenlafaxine

Anatomical Therapeutic Chemical (ATC) Classes for desvenlafaxine

US Patents and Regulatory Information for desvenlafaxine

Market Dynamics and Financial Trajectory for Desvenlafaxine